✨ Free AI Report
Pharmaron Beijing Co., Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Pharmaron Beijing Co., Ltd.
Company Research

Pharmaron Beijing Co., Ltd.: Business Overview, Financials & Competitive Analysis

Pharmaron Beijing Co., Ltd. scores 7/10 on the AskCyborg Cyborg Score (Strong). Pharmaron represents a well-capitalized, growing CDMO/CRO platform with strong execution in drug development services and exposure to high-value emerging therapeutics. Pharmaron demonstrates solid fundamentals with $7.1B market cap, $1.7B revenue (2024), and 21,370 employees, reflecting significant scale in the CDMO/CRO market. Strong growth trajectory and diversified service offerings.

What is Pharmaron Beijing Co., Ltd.'s industry? Pharmaron Beijing Co., Ltd. (www.pharmaron.cn) operates in Pharmaceutical Research and Development Services (CDMO/CRO). AskCyborg classifies Pharmaron Beijing Co., Ltd. under Pharmaceutical Research and Development Services (CDMO/CRO) in its company registry.

Pharmaron Beijing is a comprehensive pharmaceutical research and development service provider founded in 2004, offering full-spectrum drug discovery, development, and manufacturing services. The company serves pharmac...

7/ 10Strong

Cyborg Score thesis

Pharmaron represents a well-capitalized, growing CDMO/CRO platform with strong execution in drug development services and...

Read the full analyst-debate transcript →
Industry Pharmaceutical Research and Development Services (CDMO/CRO)
3 named competitors
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Pharmaron Beijing Co., Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Pharmaron Beijing Co., Ltd.

AskCyborg analysts argue the bull and bear cases for Pharmaron Beijing Co., Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Pharmaron Beijing Co., Ltd. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Pharmaron Beijing Co., Ltd. Overview

Pro stress-test →

Pharmaron Beijing is a comprehensive pharmaceutical research and development service provider founded in 2004, offering full-spectrum drug discovery, development, and manufacturing services. The company serves pharmaceutical and biotechnology clients globally, spanning small molecule drugs, cell therapies, and gene therapies across multiple geographic markets.

Strategic Profile

Pro stress-test →

Pharmaron operates as a full-service CDMO and CRO with integrated capabilities spanning laboratory services, chemical and formulation development, clinical research, and macromolecule/cell & gene therapy services. The company's diversified service portfolio and global footprint position it as a key enabler for biotech innovation, with particular strength in emerging therapies like ADCs and gene therapies.

Competitive Landscape

Pro stress-test →

Pharmaron competes in the CDMO/CRO space alongside global players like Wuxi AppTec, Asymchem, and international firms (Thermo Fisher, Charles River), as well as emerging Chinese providers. Its competitive differentiation centers on integrated full-service capabilities, emerging therapy expertise (ADCs, cell/gene therapy), and established client relationships across pharma's innovation pipeline.

Industry Context

Pharmaron Beijing Co., Ltd. operates in Pharmaceutical Research and Development Services (CDMO/CRO).

Key facts

Founded: 2004 · Headquarters: Beijing, China · Employees: 21,370 · Revenue: $1.7B · Market cap: $7.1B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Pharmaron Beijing Co., Ltd..

  • Full-spectrum service offering from drug discovery through commercialization provides integrated value chain for pharma clients
  • Diversified therapeutic expertise including ADCs, cell therapies, and gene therapies captures growth in next-generation drug modalities
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Integrated CDMO/CRO ServicesCompeting integrated drug discovery and manufacturing services provider→CDMO ServicesChinese CDMO competitor with chemical manufacturing focus→Contract Research ServicesGlobal CRO/preclinical services provider→

Compare Pharmaron Beijing Co., Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Pharmaron Beijing Co., Ltd. operates in Pharmaceutical Research and Development Services (CDMO/CRO). See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Research and Development Services (CDMO/CRO) research →
NEW · MCP server

Ask your AI assistant about Pharmaron Beijing Co., Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Pharmaron Beijing Co., Ltd. and its top competitor on Cyborg Score”
“What did Pharmaron Beijing Co., Ltd. do this quarter?”
“Is Pharmaron Beijing Co., Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Pharmaron Beijing Co., Ltd. do?+
Pharmaron Beijing is a comprehensive pharmaceutical research and development service provider founded in 2004, offering full-spectrum drug discovery, development, and manufacturing services. The company serves pharmac...
What is Pharmaron Beijing Co., Ltd.'s Cyborg Score?+
Pharmaron Beijing Co., Ltd. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Pharmaron Beijing Co., Ltd.'s main competitors?+
Named competitors include Integrated CDMO/CRO Services, CDMO Services, Contract Research Services. The full competitive landscape is in the AskCyborg report.
How can I get the full Pharmaron Beijing Co., Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Pharmaron Beijing Co., Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Pharmaron Beijing Co., Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.